Vertex Pharmaceuticals VRTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $12.22B+1.8% | $12B+2.4% | $11.72B+2.7% | $11.42B+2.9% | $11.1B+0.7% | ||
| $1.68B+1.8% | $1.65B+2.6% | $1.61B+1.4% | $1.59B+2.3% | $1.55B+1.3% | ||
| $10.54B+1.8% | $10.35B+2.3% | $10.11B+2.9% | $9.83B+3.0% | $9.55B+0.6% | ||
| 86.2%0.0pp | 86.2%0.0pp | 86.3%+0.2pp | 86.1%+0.1pp | 86%-0.1pp | ||
| $1.85B+5.6% | $1.75B+6.7% | $1.64B+4.7% | $1.57B+3.5% | $1.52B+3.7% | ||
| $7.54B-3.7% | $7.83B+1.3% | $7.73B+3.1% | $7.5B-36.7% | $11.84B+5.2% | ||
| $4.68B+12.2% | $4.17B— | —— | —— | —— | ||
| 38.3%+3.5pp | 34.8%— | —— | —— | —— | ||
| $5.17B+11.3% | $4.64B+4.4% | $4.45B+1.7% | $4.37B+1,557% | -$300.2M-221% | ||
| $827.4M+19.9% | $690M-10.8% | $773.6M+5.1% | $736.4M+6.9% | $688.7M-12.2% | ||
| $4.34B+9.7% | $3.95B— | —— | —— | —— | ||
| 35.5%+2.6pp | 32.9%— | —— | —— | —— | ||
| $16.85+10.0% | $15.32— | —— | —— | —— | ||
| $4.9B+11.8% | $4.38B+1.8% | $4.31B+1.7% | $4.24B+1,092% | -$426.9M-587% | ||
| 40.1%+3.6pp | 36.5%-0.2pp | 36.7%-0.4pp | 37.1%+40.9pp | -3.8%-4.6pp | ||
| $4.68B+12.2% | $4.17B+1.6% | $4.11B+1.7% | $4.04B+742% | -$629M-426% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Vertex Pharmaceuticals's revenue?
- Vertex Pharmaceuticals (VRTX) generated $12.2B in revenue over the trailing twelve months, up 10.1% year over year.
- Is Vertex Pharmaceuticals profitable?
- Vertex Pharmaceuticals reported $4.3B in net income over the trailing twelve months, a 35.5% net margin.
- What are Vertex Pharmaceuticals's profit margins?
- Gross margin is 86.2% and operating margin is 38.3%, with a 35.5% net margin.
- What is Vertex Pharmaceuticals's earnings per share?
- Vertex Pharmaceuticals's diluted EPS over the trailing twelve months is $16.85.
- Where does Vertex Pharmaceuticals's income statement data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
